From gene editing to vaccine manufacturing, biotech is becoming a tool of sovereignty.
Biotechnology is no longer just about healthcare and pharmaceuticals. From CRISPR gene editing to vaccine manufacturing and biosecurity platforms, biology is being reimagined as a lever of sovereignty. Nations are pouring capital into labs, infrastructure, and supply chains to secure independence in everything from food systems to pandemic defense. This is a race for resilience and influence, and it is reshaping global markets in real time. For investors, the implications are profound: biotech is becoming not only a growth industry but also a national security asset.